HC Deb 02 July 1993 vol 227 c646W
Ms Primarolo

To ask the Secretary of State for Health if she will make a statement on the use of AZT with HIV-positive patients of different age groups in the national health service.

Mr. Sackville

Zidovudine—AZT—is currently licensed in the United Kingdom and the European Community for use in the following circumstances:

  • —asymptomatic disease in adult patients showing signs of immune suppression ie. CD4 count repeatedly below 200 per cubic millimetre (cumm) or between 500 and 200 and falling rapidly;
  • —early symptomatic HIV disease in adults with CD4 counts below 500 per cubic millimetre:
  • —advanced disease ie. AIDS and AIDS related complex, in adults and children;
  • —HIV related symptoms or asymptomatic disease with markers indicating significant HIV-related immune suppression in children over the age of three months.

Forward to